10 Years From Now in Oncology
Welcome to ‘10 Years From Now in Oncology’, MEDSIR’s exclusive newsletter
At MEDSIR, we specialize in designing and managing cutting-edge clinical trials to advance oncology research worldwide. Our mission is to transform patient outcomes by collaborating with experts, leveraging innovation, and unlocking the full potential of data-driven research.
Through this newsletter, we invite you to explore groundbreaking studies, key milestones, and insights from the forefront of cancer research.
QUICK READ
This edition's highlights:
Special Event: Join us at the ISTs Innovation Forum during WCLC 2025 in Barcelona
Clinical Spotlight: Exclusive interview with Dr. María Gion on the ATRACTIB study
Expert Insights: Dr. Thorsten Füreder discusses HER3-DXd in NSCLC with activebrain metastases
More Highlights: BioSpace article on bridging clinical needs and drug development and New Publication: PATHFINDER study results published in Breast Cancer Research
Join Our Team: Explore open positions at MEDSIR
Join Us at the ISTs Innovation Forum – WCLC 2025, Barcelona
We’re thrilled to host the ISTs Innovation Forum during the World Conference on Lung Cancer (WCLC) in Barcelona!
📅 Date: September 6th, 2025
🕕 Time: 6:00 PM
📍 Location: Renaissance Barcelona Fira Hotel
This exclusive event brings together global oncology leaders and emerging changemakers to co-design high-impact investigator-sponsored trials (ISTs). With only 25 spots available, participants will engage in interactive workshops, panel discussions, and networking sessions with top international KOLs including:
Dr. Alfredo Addeo (Switzerland)
Dr. Arsela Prelaj (Italy)
Dr. Patrick Forde (Ireland)
Dr. Kaushal Parikh (US)
Dr. Stephanie Saw (Singapore)
🔗Apply now to secure your spot! https://www.medsir.org/events/istsforum
Clinical Spotlight: ATRACTIB Study in aTNBC
Following the recent publication of the ATRACTIB study in Nature Medicine, we sat down with Dr. María Gion Cortés (Hospital Universitario Ramón y Cajal and Hospital Beata Maria Ana, Madrid) to explore the clinical impact of the combination of atezolizumab, bevacizumab, and paclitaxel in advanced triple-negative breast cancer (aTNBC).
Triplet Therapy Effective in Advanced TNBC: ATRACTIB Trial Results
📺 Watch the full interview:
Key findings from the Phase II trial:
PFS: 11.0 months
ORR: 63.0% (including 14% complete responses)
Median OS: 27.4 months
PD-L1–negative tumors: 97.6% of evaluable cases
Safety: Manageable profile with no treatment-related deaths
These results underscore the potential of combining chemotherapy, immunotherapy, and antiangiogenics—and open the door to future combinations with antibody-drug conjugates.
Nature Medicine publication: https://www.nature.com/articles/s41591-025-03734-3
Read more on ESMO News
TUXEDO-3 Study: HER3-DXd in NSCLC with active Brain Metastases
In Lung Cancers Today, Dr. Thorsten Füreder Füreder (Medizinische Universität Wien) shares insights on the TUXEDO-3 study, evaluating patritumab deruxtecan (HER3-DXd) in patients with advanced NSCLC and active brain metastases. TUXEDO-3 results were featured in an oral presentation at ASCO 2025
📽️ Watch the interview and read the article:
More on TUXEDO-3 at Nature Medicine
We’re proud to highlight the recent publication in Nature Medicine featuring results from the TUXEDO-3 study cohort 3, evaluating HER3-DXd in patients with leptomeningeal metastatic disease from solid tumors
Key findings from cohort 3:
3-month overall survival rate: ~70%
Median survival: 6.1 months
Intracranial clinical benefit rate: 50%
Neurological symptoms and quality of life: Stable or improved
Safety: Most common adverse events were hematologic and gastrointestinal
These results position HER3-DXd as a promising therapeutic option for a patient population with limited treatment alternatives and high unmet need.
More Highlights
PATHFINDER Study: New data published in Breast Cancer Research explores ipatasertib combinations in previously treated aTNBC. Capecitabine and eribulin showed acceptable safety and a potential efficacy signal; carboplatin + gemcitabine led to high toxicity. 🔗 Read the full manuscript
BioSpace feature: A must-read article on bridging the gap between drug development and real-world clinical needs in oncology. 🔗 Read it here
Job Vacancies at MEDSIR
We’re growing, and we want you to be part of our journey. Check out our latest job openings and join us in shaping the future of clinical research.
o Clinical Development Specialist
Subscribe to Stay Updated
Follow our journey as we explore innovations in oncology research and share milestones that bring us closer to better care for cancer patients.